CORNING, N.Y.--(BUSINESS WIRE)--Corning Incorporated (NYSE:GLW) today announced that Daiichi-Sankyo Co. Ltd. purchased the Corning® Epic® System for installation and integration into drug discovery operations at its Kasai Research & Development Center in Tokyo. Daiichi-Sankyo is a global pharmaceutical innovator and Japan’s second-largest drug maker. This purchase marks the entry of Corning’s microplate-based, label-free drug screening platform into the Japanese pharmaceutical market, following successful commercial launches in both North America and Europe.
